Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples

Brief summary public domain (ClinicalTrials.gov)

The goal of this observational study is to test in patients with cystic tumor of pancreas. The main questions it aims to answer are: Screening of molecular diagnostic markers for pancreatic cystic tumors by cfDNA methylation sequencing of pancreatic cystic fluid and proteomic assays to distinguish benign from malignant and mucinous/non-mucinous, correlate with pathological features, and find molecular features associated with the degree of malignancy. Participants will Provide post-operative cyst fluid specimens.

Detailed description public domain (ClinicalTrials.gov)

Patients with pancreatic cystic tumors were divided into control, mucinous tumor and non-mucinous tumor groups, and cfDNA molecules and protein molecules that were significantly altered between different groups were found by cfDNA methylation sequencing of pancreatic cystic fluid and proteomic detection techniques. Multi-omics analysis was performed to construct a more efficient molecular diagnostic marker model. Correlating models with pathological features to find molecular features associated with the degree of malignancy.

Intervention public domain (ClinicalTrials.gov)

Diagnostic_Test: cfDNA methylation sequencing and proteome analysis. Sequencing of cfDNA methylation and proteomic analysis of two sets of capsular fluid samples

Arm public domain (ClinicalTrials.gov)

Mucinous tumour group ():

Arm public domain (ClinicalTrials.gov)

Non-mucinous tumour group ():

Primary outcome public domain (ClinicalTrials.gov)

Types and concentrations of cfDNA and proteins contained in the vesicular fluid. Identification of protein and circulating gene methylation species in cyst fluid and quantification of their concentrations using mass spectrometry. Characterize cfDNA methylation and proteomics of cyst fluid in patients with pancreatic cystic neoplasm (PCN). Time frame: 2023-11-31.

Secondary outcome public domain (ClinicalTrials.gov)

Establishment of a diagnostic model for cystic tumors of the pancreas. Time frame: 2023-11-31.

Secondary outcome public domain (ClinicalTrials.gov)

Establishing a model for the identification of mucus and non-mucus. Time frame: 2023-11-31.

Secondary outcome public domain (ClinicalTrials.gov)

Development of a progressive benign malignancy prediction model. Time frame: 2023-11-31.

Eligibility public domain (ClinicalTrials.gov)

Inclusion Criteria: * Subjects are ≥ 18 years old, regardless of gender; * Preoperative imaging examination (EUS, CT, MRI) diagnosed cystic mass of pancreas and suspected cystic tumor; * Subjects voluntarily accepted radical resection of pancreatic cystic tumors; * Subjects or family members voluntarily sign the informed consent form for clinical research. Exclusion Criteria: * The excised sample does not contain cystic components, or the cystic fluid cannot be collected; * Receive tumor-related treatment (radiotherapy, chemotherapy, immunotherapy, etc.) before operation; * Receive antibiotic treatment within 1 week before operation; * Subjects refused to accept radical resection of pancreatic cystic tumor, or had any situation that they could not accept radical resection of pancreatic cystic tumor; * The subjects or their families refused to sign the informed consent form for clinical research.

Enrollment public domain (ClinicalTrials.gov)

Enrollment: 100 participants (estimated).